Enterococcus faecium is not an exotic microbe. It lives quietly in the human gut, but in hospitals it has become a leading cause of bloodstream infections, wound infections and endocarditis, particularly in patients weakened by surgery, broad-spectrum antibiotics or invasive devices. What makes E. faecium a global public health threat is its extraordinary capacity to acquire resistance. The emergence of vancomycin-resistant E. faecium, known as VREfm, has drastically narrowed treatment options, because vancomycin has long been one of the few reliable drugs against enterococcal infections. The World Health Organization has flagged vancomycin-resistant enterococci as high-priority targets for new antibiotic development, and genomic surveillance has become the sharpest available tool for tracking how these bacteria spread and evolve inside hospitals.

In the new study, the two clinical isolates, designated EF_35 and EF_38, were recovered from surgical site infections in two different hospitalised patients treated in obstetrics and gynaecology departments. Both patients had developed post-operative wound infections, a well-known complication of caesarean sections and other surgical procedures. The research team performed antibiotic susceptibility testing, whole-genome sequencing and a battery of bioinformatic analyses designed to answer three key questions: what resistance genes did the bacteria carry, on what mobile elements were those genes located, and how closely related were the two isolates to each other and to E. faecium genomes reported elsewhere in the world.

The answer to the relatedness question was striking. Multilocus sequence typing placed both isolates in sequence type 80, or ST80, a lineage belonging to clonal complex CC17, the group of hospital-adapted E. faecium strains that has spread through healthcare systems worldwide since it first emerged as a nosocomial clone. Even more telling, whole-genome single nucleotide polymorphism analysis revealed that the two isolates differed by only eight genomic SNPs. In practical terms, bacteria from different patients that differ by only a handful of SNPs are considered closely related, strongly suggesting a common source or direct transmission within the hospital environment. An interval of twenty days between the two isolations fits the classic pattern of a nascent hospital outbreak, in which a single strain moves between patients, surfaces or healthcare workers before being detected.

Genetically, the isolates were textbook multidrug-resistant VREfm. Phenotypic testing confirmed resistance to vancomycin, and the genomes harboured genes conferring resistance to aminoglycosides and macrolides as well. This stacking of resistance determinants is what makes CC17 lineages so successful in hospitals: a patient colonised by such a strain who then develops an infection has very few oral or intravenous options, and clinicians are pushed toward last-line agents such as linezolid or daptomycin, drugs that are expensive, toxic and themselves threatened by emerging resistance.

The centrepiece of the genomic analysis was the vanA operon, the genetic machinery that renders enterococci resistant to vancomycin and teicoplanin. Vancomycin normally works by binding the D-Ala-D-Ala termini of peptidoglycan precursors, blocking cell-wall synthesis. The vanA system rewires that target: it enzymatically remodels cell-wall precursors to end in D-Ala-D-Lac instead, an terminus to which vancomycin binds with drastically reduced affinity, while simultaneously degrading the normal precursors. In both Algerian isolates, the researchers found the vanA operon embedded within a Tn1546 transposon-like element, the mobile genetic unit first characterised in the 1990s in the French reference strain E. faecium BM4147 and since then responsible for disseminating glycopeptide resistance around the globe.

Crucially, that Tn1546 element was not sitting on the chromosome. It was located on a rep17-type plasmid, a replicon family related to the well-known pRUM plasmids that circulate among hospital E. faecium strains. Plasmids are circular, self-replicating DNA molecules that can transfer horizontally between bacteria, sometimes across species boundaries, and they are widely regarded as the primary vehicles by which resistance genes move through hospital microbial communities. Recent work has shown that plasmids were central to the recent emergence of E. faecium as a major nosocomial pathogen, so pinpointing which plasmid carries a resistance cassette in a given region provides both an evolutionary and an epidemiological clue.

One detail of the plasmid’s cargo raised the stakes considerably. Alongside the vanA-Tn1546 cassette, the rep17 plasmid also carried a specific resistance locus, designated locus 3, composed of the genes ant(6), sat(4) and aph(3′). This exact gene combination has drawn attention because it has been found in vancomycin-resistant Staphylococcus aureus, the feared VRSA isolates in which the vanA operon has jumped from enterococci into staphylococcal genomes, including cases in which the entire vanA locus integrated into the S. aureus chromosome. The presence of the same Tn1546-associated aminoglycoside locus on an E. faecium plasmid in Algeria raises, as the authors note, the possibility that such a plasmid could transfer the vanA operon into a staphylococcal genome. Although VRSA remains rare worldwide, each documented case has followed precisely this route of plasmid-mediated gene transfer from enterococci to staphylococci, so plasmids of this architecture are watched as potential launching pads for that dangerous jump.

For Algeria specifically, the study fills in an important piece of a growing picture. Earlier reports documented the first vancomycin-resistant enterococcal cases in the country in 2008, the emergence of glycopeptide-resistant E. faecium in subsequent years, molecular characterisation of related vanA E. faecium healthcare-associated infections, and a 2021 survey showing high frequency and diversity of VRE in Algerian healthcare settings, followed by the detection of vanA-positive E. faecium CC17 even in hospital wastewater. The new genomic data demonstrate that the epidemic VREfm ST80 clone is not merely present but actively evolving within Algerian hospitals, carrying the same mobile resistance elements described on other continents. Genomic surveillance of this kind, the authors argue, is essential for detecting clonal transmission early enough to interrupt it with infection-control measures, from hand hygiene and environmental disinfection to active screening and isolation of colonised patients.

The technical approach also illustrates how modern clinical microbiology increasingly relies on whole-genome sequencing as a routine investigative tool. By combining sequencing with tools for plasmid detection and typing, transposon annotation, resistome identification and SNP-based phylogenetic comparison, the team could reconstruct, from two wound isolates, a narrative of clonal spread, plasmid-borne resistance and cross-genus transmission risk that older methods such as pulsed-field gel electrophoresis could only hint at. The genomes of both isolates have been deposited in GenBank under accession numbers JBAIVL000000000 and JBAIVM000000000, making them available for future comparative studies across the Mediterranean region and beyond.

The broader message is sobering but not hopeless. VREfm ST80 is now documented on multiple continents, and the genetic elements that give it its armour are inherently mobile. Yet the same mobility that makes the threat means surveillance works: identifying a rep17 plasmid carrying Tn1546-vanA in a specific hospital department tells infection-control teams exactly what to look for and where to intervene. For obstetric and gynaecology patients, who undergo some of the most common surgeries in medicine, keeping this clone from gaining a foothold is a matter of routine vigilance, genomic alertness and the unglamorous but decisive practice of infection prevention.

The notable findings stem from a comprehensive genomic analysis that reveals the unique characteristics of the newly identified bacteriophage. Phages, which are viruses that specifically infect bacteria, have garnered renewed interest as potential alternatives to antibiotics, particularly as antibiotic resistance continues to emerge at alarmingly high rates. By examining this phage from a genomic perspective, the researchers have laid the groundwork for understanding its functionality at a molecular level, including its infection mechanisms and structural attributes that make it effective against Pseudomonas aeruginosa.

In their investigation, Unlu and Uskudar Guclu conducted a series of in vitro tests to ascertain the antimicrobial and antibiofilm properties of the new bacteriophage. Pseudomonas aeruginosa is notorious for forming biofilms, which are complex communities of microorganisms that adhere to surfaces and are encased in a protective matrix. These biofilms significantly complicate treatment protocols, rendering conventional antibiotics less effective. The discovery that Angoravirus has the capability to disrupt biofilm formation and kill bacteria within these structures positions it as a promising candidate for phage therapy.

The phage application offers a multifaceted strategy for combating bacterial infections. Unlike traditional antibiotics, which can indiscriminately kill a wide range of bacteria including beneficial flora, phages are highly specific, targeting only particular bacterial strains. This selectivity not only preserves the natural microbiome but also diminishes the chance of developing secondary infections. The unique genomic traits of Angoravirus, as outlined in the study, may bolster its ability to not only attack free-floating bacteria but also penetrate complex biofilm structures.

One of the pivotal aspects of this research resides in the phage’s genomic composition. Through meticulous bioinformatics analyses, the researchers delineated the evolutionary relationships between Angoravirus and other known phages. This analysis suggests evolutionary pathways that could be exploited for phage engineering, potentially enhancing their therapeutic efficacy. The researchers highlighted the genetic elements that confer virulence and replication advantages, a critical advantage when considering phage therapy for clinical applications.

In addition to characterizing the genomic features of Angoravirus, the study assessed its in vitro efficacy against clinical isolates of Pseudomonas aeruginosa. The testing revealed remarkable potency, achieving a significant reduction in bacterial counts. The results from this preliminary study herald the potential of Angoravirus as more than just a biological curiosity; it may soon evolve into a substantial player in the antibiotic resistance arena.

The implications of this research extend far beyond the laboratory bench. The ability of Angoravirus to effectively combat biofilms could reshape treatment paradigms for chronic infections caused by Pseudomonas aeruginosa, particularly in immunocompromised patients. The versatility of phages allows them to be used in conjunction with existing antibiotics, potentially enhancing the effectiveness of traditional therapies and leading to better patient outcomes.

As we examine the broader impacts of this study, it is essential to consider the regulatory and practical challenges that lie ahead in phage therapy development. While phage therapy is not a novel concept, its transition from bench to bedside requires navigating complex regulatory frameworks that govern therapeutic agents. The inclusion of a newly discovered genus further complicates these proceedings, as safety and efficacy must be thoroughly evaluated in clinical settings.

Moreover, public perception of phage therapy remains an area of active discourse. Many healthcare professionals and patients are unfamiliar with phages as a potential treatment modality. Thus, educational initiatives to disseminate knowledge about bacteriophages—coupled with clinical data highlighting their successes—will be crucial in cultivating an environment conducive to the adoption of phage therapies.

The collaboration between researchers Unlu and Uskudar Guclu marks a significant step towards overcoming one of the greatest challenges in modern medicine: antibiotic resistance. Their work exemplifies the interdisciplinary approach needed to tackle complex health issues, integrating genomics, microbiology, and clinical research. As advancements continue, the prospect of utilizing Angoravirus and similar phages could redefine how we approach bacterial infections, emphasizing the need for innovative solutions in an era dominated by antibiotic resistance.

In summary, the findings from this study represent a promising advancement in our understanding of phage therapy and its potential applications against Pseudomonas aeruginosa. The genomic characterization of Angoravirus not only enriches our catalog of bacteriophages but also opens new avenues for research and therapeutic intervention. As the realm of infectious diseases evolves, particularly in the context of antibiotic resistance, the integration of bacteriophages into clinical practice could significantly alter the landscape of infection control and management.

With ongoing research, clinical trials will be essential to confirm the in vitro findings and to explore the potential for phage therapy in real-world clinical settings. The journey from discovery to application is complex and requires a multi-faceted approach involving collaboration between scientists, clinicians, and regulatory bodies. But if successful, Angoravirus might just represent a beacon of hope in the struggle against one of medicine’s most formidable adversaries: multidrug-resistant bacteria.

Subject of Research: Genomic characterization of a novel Pseudomonas aeruginosa bacteriophage, Angoravirus.

Article Title: Genomic characterization of a novel Pseudomonas aeruginosa bacteriophage representing the newly proposed genus Angoravirus: in vitro antimicrobial and antibiofilm activity.

Article References:

Unlu, S., Uskudar Guclu, A. Genomic characterization of a novel Pseudomonas aeruginosa bacteriophage representing the newly proposed genus Angoravirus: in vitro antimicrobial and antibiofilm activity.
Int Microbiol (2025). https://doi.org/10.1007/s10123-025-00669-0

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s10123-025-00669-0

Keywords: bacteriophage, Pseudomonas aeruginosa, Angoravirus, antimicrobial, antibiofilm, antibiotic resistance.